EUVIMEDEUVIMED entdecken
Crossref

CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives

Jeremy D. Rubinstein, Colleen Annesley, Deepa Bhojwani, Sara Ghorashian, Johann Hitzler, Rishi S. Kotecha, Joerg Krueger, Susana Rives, Anupam Verma, Sara Zarnegar‐Lumley, Nirali N. Shah, Karen R. Rabin

British Journal of Haematology · 19.11.2026

DOI: 10.1111/bjh.70945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 19.11.2026. Verfasst von Jeremy D. Rubinstein und 11 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, European Commission.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of B‐cell acute lymphoblastic leukaemia (B‐ALL) in patients with Down syndrome (DS‐ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS‐ALL, optimal management is uncertain. Chimeric antigen receptor T‐cell (CAR‐T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non‐DS patients. We distributed an international survey to paediatric oncologists treating DS‐ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR‐T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra‐medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR‐T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%–15% for early relapse; 3%–5% for late relapse. The main perceived benefit of CAR‐T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high‐risk relapse of DS‐ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR‐T is warranted for first relapse in DS‐ALL.

Förderung

  • Instituto de Salud Carlos III
  • European Commission

Zitieren

APA

Rubinstein, J. D., Annesley, C., Bhojwani, D., Ghorashian, S., Hitzler, J., Kotecha, R. S., Krueger, J., Rives, S., Verma, A., Zarnegar‐Lumley, S., Shah, N. N., & Rabin, K. R. (2026). CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives. British Journal of Haematology. https://doi.org/10.1111/bjh.70945

Vancouver

Rubinstein JD, Annesley C, Bhojwani D, Ghorashian S, Hitzler J, Kotecha RS, et al. CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives. British Journal of Haematology. 2026. doi:10.1111/bjh.70945

BibTeX
@article{Rubinstein2026,
  author = {Rubinstein, Jeremy D. and Annesley, Colleen and Bhojwani, Deepa and Ghorashian, Sara and Hitzler, Johann and Kotecha, Rishi S. and Krueger, Joerg and Rives, Susana and Verma, Anupam and Zarnegar‐Lumley, Sara and Shah, Nirali N. and Rabin, Karen R.},
  title = {CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70945}
}
Kostenlos starten →